Tag Archive for: Southern Research Institute

Robert Galemmo joins the Southern Research Institute as Senior Medicinal Chemist

Life Science Partner recruits former Senior Scientist at Elan Pharmaceuticals

 Life Science Partner announces the recruitment of Robert Galemmo, PhD, to the Southern Research Institute in Birmingham, Alabama.

Southern Research Institute is an independent, not-for-profit center for scientific research  organization with a focus on the discovery and advancement of new, small-molecule therapeutics from the design stage to the clinic, Southern Research Institute’s Drug Discovery Research Division has accomplished innovative research in the areas of cancer, infectious disease and neuroscience.

At Elan Pharmaceuticals, Galemmo oversaw the leadership of two chemistry efforts in the discovery of highly selective CNS penetrant kinase inhibitors for Parkinson’s disease.  Previously, he served as Senior Director and Head of Chemistry at Neuromed Pharmaceuticals, a Vancouver-based biotechnology company focused on calcium ion channel inhibitors.

“Galemmo is a talented medicinal chemist and experienced manager of diverse scientific teams,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “His broad therapeutic area experience will serve the Institute well, as it builds upon its considerable success in drug discovery.”

Galemmo earned his Bachelor of Science Degree and PhD in Organic Chemistry from Ohio State University.

/0 Comments/by

Mark Suto joins the Southern Research Institute as Vice President of Drug Discovery

Life Science Partner recruits former Vice President, Chemical and Pharmaceutical Sciences at Icagen, Inc.

Life Science Partner announces the recruitment of Mark Suto, PhD, an experienced scientist and drug discovery executive, to the Southern Research Institute in Birmingham, Alabama.

Southern Research Institute.  With a focus on the discovery and advancement of new, small-molecule therapeutics from the design stage to the clinic, Southern Research’s Drug Discovery Research Division has accomplished innovative research in the areas of cancer, infectious disease and neuroscience.

Suto was previously Vice President at Icagen, a biopharmaceutical company focused on the novel small molecule drugs that target ion channels in diverse therapeutic areas. He was responsible for leading discovery and development chemistry activities, including medicinal, bioanalytical and computational chemistry for the company.  Previously, he served as Executive Vice President and Chief Scientific Officer at Neurion Pharmaceuticals.

“Suto is a passionate and articulate individual, with an impressive background in drug discovery,” noted Tom Callaway, MD, founder and president of Life Science Partner.  “He will bring infectious enthusiasm along with 28 years of large pharmaceutical and biotechnology experience to the team at Southern Research.”

Suto earned his Bachelor of Science Degree and PhD in Medicinal Chemistry from the State University of New York at Buffalo.

/0 Comments/by

Andrew Penman joins the Southern Research Institute as Vice President of Drug Development

Life Science Partner recruits former Vice President, Preclinical Development for Angiotech and Aptuit.

Life Science Partner announces the recruitment of Andrew Penman, an experienced scientist and preclinical development executive, to the Southern Research Institute in Birmingham, Alabama.

Southern Research Institute is an independent, not-for-profit center for scientific research providing innovative leadership in scientific discovery and drug development.  With a focus on the discovery and advancement of new, small-molecule therapeutics from the design stage to the clinic, Southern Research Institute’s Drug Discovery Research Division has accomplished innovative research in the areas of cancer, infectious disease and neuroscience.

Andrew Penman Alabama

Most recently, Penman was the Vice President of Preclinical Development for Angiotech, a global specialty pharmaceutical and medical device company, where he was responsible for managing the global preclinical business in research and development for the company.

Previously, Penman served as President of Preclinical Technologies at Aptuit (formerly Quintiles, Inc).  In his role at the Southern Research Institute, he will be responsible for providing scientific vision, strategic direction and operational management of the Drug Development Division of the Institute.

“Penman is a talented preclinical pharmaceutical development executive with broad experience in infectious diseases, oncology and cardiology drugs,” noted Tom Callaway, President of Life Science Partner. “He will successfully build upon the Institute’s considerable scientific expertise and drug development platform and further enhance their reputation as one of the nation’s premier drug discovery organizations.”

Penman received his undergraduate degree in Chemistry from the Heriot-Watt University in Edinburgh, Scotland and earned his PhD from the University of Kent in Canterbury, Kent.

Learn More About Chief Scientific and Technology Leader Recruitment
/0 Comments/by

Blaine Knight to join the Southern Research Institute as Vice President of Drug Discovery

Life Science Partner recruits former Vice President, Globalization Projects and Preclinical Development for GlaxoSmithKline

Life Science Partner announces the recruitment of Blaine Knight, an experienced scientist and drug discovery executive, to the Southern Research Institute in Birmingham, Alabama. 

Southern Research Institute is an independent, not-for-profit center for scientific research providing innovative leadership in scientific discovery, drug development, engineering, aerospace, materials, environmental and energy research, chemical and biological defense, and homeland security.   

With a focus on the discovery and advancement of new, small-molecule therapeutics from the design stage to the clinic, Southern Research Institute’s Drug Discovery Research Division has accomplished innovative research in the areas of cancer, infectious disease and neuroscience.

Most recently, Knight was the Vice President, Globalization Projects and Preclinical Development for GlaxoSmithKline, where he developed a strategy for establishing R&D facilities in Asia and identified opportunities for outsourcing and innovative science from discovery to proof of concept from the American and European GSK sites in Asia.   Knight has held several executive positions at GSK within the Discovery Research Directorate including VP, Strategic Alliances; VP, Screening Sciences; and VP, Systems Research.  Prior to his roles at GSK, he held leadership positions in the Biochemistry Division at Glaxo Wellcome and in the Division of Molecular Sciences at the Glaxo Research Institute.

“Blaine is a strong and talented scientist with global understanding of the process of discovery,” noted Cindi Roberts, vice president of Life Science Partner.  “He will successfully build upon the Institute’s considerable platform and further enhance their reputation as one of the nation’s premier drug discovery organizations.”

Knight received his undergraduate degree in Chemistry from the University of Virginia in Charlottesville and earned his Doctorate in Biochemistry from the University of Maryland in College Park.  Blaine completed his National Institutes of Health Postdoctoral Research Fellowship in Biochemistry at the University of Wisconsin-Madison, Madison, WI.

/0 Comments/by